We have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci
|
|
- Maurice Bates
- 5 years ago
- Views:
Transcription
1 We have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci
2 Pressures for new vaccine introduction. International institutions. Vaccine manufacturers National authorities (GOs). Interest groups (NGOs). Professional organisations. Public at large. Opinion formers who influence the public at large.
3 Constraints on new vaccine introduction. You think your own priorities are more important than anyone else s - ability to influence prioritisation. Resource limitations at all levels, especially for preventative rather than curative services. Competing priorities for those implementing. Lack of receptivity at local level for problems of global, regional or national relevance - a predictable consequence of decentralisation.
4 Who? How much? Where is the money? How? Why? Immunisation Who will do it? strategy When? Did it work? Where? Why not? Is it worth it?
5 Is there a need? Is there a vaccine? That is safe and effective? Who should receive vaccine? Would it be a good use of public or personal funds?
6 Is there a need? Information requirements. Epidemiology of disease: Extent of burden in morbidity and mortality. Age of affected population. Projections for future disease burden. Clinical management of disease: Primary care implications. Secondary / tertiary care implications. Long term complications of disease and health requirements. Economic burden may consider time off work for those affected or their carers.
7 Annual cases of meningococcal infection England and Wales, ,500 1, Group B Group C
8 Is there a vaccine? Not at the time of start-up. Encouragement of manufacturers to collaborate with Phase II studies. DH funding for Vaccine Evaluation Consortium in place. Large increase in DH funding in 1997 to accelerate research. Identification of specific policy related questions for DH funded research, separate to manufacturers' interests, e.g. giving men C conjugate at same time as MMR, or other vaccines.
9 Purpose of DH investment. To accelerate the availability of much needed vaccines. To answer policy related questions that manufacturers would not necessarily address. To hasten the process of license through generation of high quality data. To evaluate vaccine effects in circumstances similar to routine use (e.g. immunisation of whole schools for adverse events).
10 % of estimates that are cost effective Economic benefits in health and strategies driven by economics HPV cost effectiveness acceptability curves Vaccination of girls 12, 13, or 14 years old (Age) per QALY gained Age 12 Age 13 Age years 20 years Life long Quadrivalent vaccine at 80% coverage, with different assumptions about vaccine duration of protection, based on results of 50,000 meta-scenarios combining epidemiological and economic assumptions ,000 20,000 30,000 40,000 50,000 60,000 Threshold ( /QALY) HPV, human papillomavirus vaccine; QALY, quality adjusted life years Jit M, Choi YH, Edmunds WJ. BMJ 2008;337:a769.
11 % of estimates that are cost effective Economic benefits in health and strategies driven by economics HPV cost-effectiveness acceptability curves Vaccination of 12-year-old girls (Coverage) per QALY gained 80% 70% 90% 10 years 20 years Life long Quadrivalent vaccine at different levels of three-dose coverage, and with different assumptions about duration of protection from vaccine ,000 20,000 30,000 40,000 50,000 60,000 Threshold ( /QALY) HPV, human papillomavirus vaccine; QALY, quality adjusted life years Jit M, Choi YH, Edmunds WJ. BMJ 2008;337:a769.
12 Economic benefits in health and strategies driven by economics Incremental cost-effectiveness ratio (Assumption: Life-long protection of HPV) Programme Median ( per QALY) 5% centile 95% centile Girls aged Catch-up for girls years old Catch-up for girls years old Catch-up for girls years old Catch-up for girls years old Girls & boys at 12 years old HPV, human papillomavirus vaccine; QALY, quality adjusted life years Jit M, Choi YH, Edmunds WJ. BMJ 2008;337:a769.
13
14 Cost-effectiveness acceptability curves for the cohort model in scenarios analyses. Curves show results under routine infant vaccination (strategy A) of the effect of varying cost (per dose) of the vaccine, vaccine duration of protection (given in months following the priming and booster doses) and vaccine efficacy (VE). Vaccine May 28;31(23): doi: /j.vaccine Epub 2013 Apr 6. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Christensen H1, Hickman M, Edmunds WJ, Trotter CL.
15
16 Acquisition of resources. Cost - benefit analysis. Operational advantages. Urgency / public health concerns. Public / Professional pressures Political dimension /Government priorities.
17 Acquisition of resources MenC conjugate programme. At least four separate budget lines Vaccine purchase, promotion, service delivery (may involve two different processes, e.g primary care and school health services), implementation. Each requires separate negotiation with different groups. No guarantee that all will succeed.
18 TV ad for the launch of Hib vaccine 1992; MenC campaign Unknown disease raise awareness. Greatly feared disease manage expectations.
19 Number of cases Haemophilus influenzae type b (Hib) E&W; Confirmed cases of invasive Hib disease in England and Wales Hib vaccine introduced All ages including under five years Under five years Hib booster at 12 months introduced into the routine immunisation programme Hib Catch-up 1 Hib Catch-up Year Source HPA
20 Number of Men C cases Neisseria meningitidis type C (MenC). E&W; Introduction of the Meningococcal C vaccine Under 20 years old Over 20 years old Year Source HPA
21 Introduction of HPV vaccine - Practical issues to consider Choice of vaccine Age of vaccination. Girls (and boys?). Catch-up campaign. School based programme vs GP practice. Parent and child acceptability.
22 Delivery Primary Care or School based service? UK has extensive experience of delivering school immunisation programmes. Tuberculin testing and BCG vaccine programme. Measles Rubella (MR) vaccine catch-up. Meningitis C (MenC) vaccine campaign. School-leaving Td/IPV vaccine.
23 % Coverage (%) in MenC school cohorts by age (yrs) All Age (yrs)
24 Attitudinal Research
25 Attitudes towards vaccination Parents of 8 10 year old children (2005) Most participants were very positive - vaccination is an important parental responsibility. Mothers seemed more involved in health generally, few differences in parents views. Perception that vaccination carries risks - assumed responsibility for protecting children against risk. Protector role and MMR controversy meant they were more conscious of risks for children than for adults. Children were too young at primary school.
26 Research summary for 11 to 12 year olds key concerns (2007). Parents Vaccine safety and potential for damaging girls future fertility A licence to engage in underage and unprotected sex Consent; parents were against the idea of their year old children having the right to decide The majority supported the idea of a catch-up programme for thirteen to eighteen year olds. Girls Worried about the trauma of the injection Most girls were in favour of having the vaccination, and many felt that their parents would be supportive. Professionals In favour of the vaccine providing programme adequately resourced.
27 Setting the communications agenda Market research to Identify ideal age for vaccination Identify key messages Develop and evaluate communication materials. Introducing the full HPV story tends to lead towards confusion and rejection - the cervical cancer story is more significant and more easily understood. HPV vaccine protects against cervical cancer. The vaccine will be part of the routine immunisation programme. Parents immunise to protect their children against disease, not against the viruses that cause them.
28 Pre testing of leaflets
29
30
31
32 Press advertising 12-13s Launch ad national press
33
34
35 Branded HPV vaccine room
36 Habbo Hotel partnership Habbo has 223,000 unique female users aged Activity included: 4 x 2 hour weekly group chat sessions with NHS health advisors Mini poll question HPV branded badge awarded to 50 users who complete poll Bots walk around Habbo sharing key information about vaccine Advertorial to support the activities Traffic drives users to advertorial to find out more Spot the difference game appears on site.
37 % Uptake 100. HPV Vaccine Uptake Year Olds 2008/09, 2009/10, 2010/11, 2011/12 & 2012/ Final 2013 data: First dose 91% Second dose 90% Third dose 86% 0. Sept Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Month 1 Dose (Coh 1, 12-13y 2008/09) 2 Dose (Coh 1, 12-13y 2008/09) 3 Dose (Coh 1, 12-13y 2008/09) 1 Dose (Coh 7, 12-13y 2009/10) 2 Dose (Coh 7, 12-13y 2009/10) 3 Dose (Coh 7, 12-13y 2009/10) 1 Dose (Coh 8, 12-13y 2010/11) 2 Dose (Coh 8, 12-13y 2010/11) 3 Dose (Coh 8, 12-13y 2010/11)
38
39 Training slide sets 39
40 Learning outcomes After completing this training resource, healthcare practitioners will be able to: Describe the aetiology and epidemiology of rotavirus Have an understanding of how rotavirus is transmitted and the potential complications of infection in infants Discuss the importance of vaccination against rotavirus Have a knowledge of the contraindications for rotavirus vaccination Safely administer the vaccine Have an understanding of potential adverse reactions and how to report these Be aware of sources of additional information 40 The infant rotavirus vaccination programme
41 _update_2016_week_06.pdf
42 Vaccine Supplies. You cannot run a new vaccine programme unless supplies are in place before the start date
43 Vaccine Supplies. You cannot run a new vaccine programme unless supplies are in place before the start date
44 The process of introducing new vaccines. Epidemiology before and after implementation. Cost-effectiveness analysis with modelling of expected impact Resources Training for Health Professionals with nationally developed materials. Supply arrangements selection, purchase, distribution. Surveys of public attitudes, knowledge and acceptability. Communications research and pre-testing of advertising materials. Development of communications packages (Television, radio, leaflets, newspapers, social networking, internet). Tracking of vaccinations through national systems. Adverse event monitoring Evaluation of communication materials. Impact assessment.
45 Elements of new vaccination Vaccine delivery - supply, clinics Surveillance of coverage Surveillance of population susceptibility Surveillance of diseases programmes Budget & resource Vaccine development Policy development Predicting the future - modelling Training Communication Planning, Implementation, Coordination, Management. Monitoring attitudes to vaccination Adverse events surveillance
Consumer acceptance: a new dimension in vaccinology
Consumer acceptance: a new dimension in vaccinology Zoltan Bozoky Department of Health - England Content Talking to parents Talking to our audience - HPV vaccine Conclusions Talking to parents 30 waves
More informationImpact and effectiveness of national immunisation programmes. David Green, Nurse Consultant, Immunisations Public Health England
Impact and effectiveness of national immunisation programmes David Green, Nurse Consultant, Immunisations Public Health England Session objectives Immunisation planning and implementation The impact and
More informationThe English immunization programme
The English immunization programme Mary Ramsay Head of Immunisation Public Health England National Health Service Constitution (2009) You have the right to receive the vaccinations that the Joint Committee
More informationThe schedule for childhood vaccination is:(web link to NHS Childhood Immunisation Schedule for 2008
Immunisations and vaccinations Immunisation is an effective public health intervention for promoting good health and protecting individuals and populations against serious disease and infection through
More informationPneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections
Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths
More informationA view from the ground what have we learned? Joanne Yarwood National Programme Manager Public Health England 1 st February 2017
A view from the ground what have we learned? Joanne Yarwood National Programme Manager Public Health England 1 st February 2017 Vaccine delivery - supply, clinics Vaccine development Communication PLANNING
More informationChanges to the Meningococcal C conjugate (MenC) vaccine schedule. Questions and Answers
Changes to the Meningococcal C conjugate (MenC) vaccine schedule Questions and Answers Background The meningococcal C (MenC) vaccination programme was first introduced into the UK routine immunisation
More informationManaging public concerns. Jo Yarwood Department of Health England
Managing public concerns Jo Yarwood Department of Health England As of 12 May 2011, more than 10,000 cases of measles and four deaths have been reported from 18 European Union/European Economic Area countries
More informationNational Immunisation Programme changes Michael Baker. Wessex Public Health England Centre
National Immunisation Programme changes 2013-14 Michael Baker Wessex Public Health England Centre Changes to the Meningococcal serogroup C conjugate (MenC) vaccine schedule in 2013 2 Immunisation Programme
More informationSubject: NHS Screening and Immunisation Programmes T
Report of the West Yorkshire Screening and Immunisation Team to the meeting of the Health and Social Care Overview & Scrutiny Committee to be held on 7 December 2017 Subject: NHS Screening and Immunisation
More informationChildhood immunisation: An Update
Childhood immunisation: An Update Helen Bedford Senior Lecturer in Children s Health UCL Institute of Child Health h.bedford@ucl.ac.uk June 11 th 2013 Immunisation Part of Healthy Child Programme HVs and
More informationGlobal Burden of Meningococcal Disease. Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci. Centre for Global Health Security, Chatham House, London.
Global Burden of Meningococcal Disease Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci. Centre for Global Health Security, Chatham House, London. Neisseria meningitidis Gram negative diplococci. Ten
More informationChanges to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered
Changes to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered healthcare practitioners Frequently asked questions August
More informationIMMUNISATION PROGRAMMES IN NHS GREATER GLASGOW AND CLYDE
NHS Greater Glasgow & Clyde NHS BOARD MEETING Jennifer Reid and Dr Syed Ahmed 16 th August 2016 Paper No: 16/51 Insert Title of NHS Board Paper Here IMMUNISATION PROGRAMMES IN NHS GREATER GLASGOW AND CLYDE
More informationESCMID Online Lecture Library
What would be the best schedule for prevention of meningococcal disease in all ages? Ray Borrow ray.borrow@phe.gov.uk Public Health England, Manchester, UK MCC vaccine programme - UK In November 1999,
More informationHealth technology Four strategies for the control of serogroup C meningococcal disease (CMD) were examined. These were:
Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease De Wals P, Nguyen V H, Erickson L J, Guay M, Drapeau J, St-Laurent J Record Status This is a critical
More informationI protected my future
I protected my future I had all my vaccinations Ask at home today if you ve had your vaccinations. Developed by Pfizer Ltd in collaboration with PHE and Wiltshire Council. March 2014. NPSC0069c Everybody
More informationUNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013
UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013 Presentation overview Scope of UNICEF procurement Overview of UNICEF procurement Vaccine market updates UNICEF procures
More informationThe next steps
Greater Manchester Hepatitis C Strategy The next steps 2010-2013 Endorsed by GM Director of Public Health group January 2011 Hepatitis Greater Manchester Hepatitis C Strategy 1. Introduction The Greater
More informationUNSCHEDULED VACCINATION OF CHILDREN AND YOUNG PEOPLE WHO HAVE OUTSTANDING ROUTINE IMMUNISATIONS. Service Specification
UNSCHEDULED VACCINATION OF CHILDREN AND YOUNG PEOPLE WHO HAVE OUTSTANDING ROUTINE IMMUNISATIONS Service Specification National Enhanced Service Specification For The Unscheduled Vaccination Of Children
More informationMumps in the Community Dr. Isabel Oliver, A Webber Training Teleclass
Overview MUMPS in the Community Dr. Isabel Oliver Consultant Regional Epidemiologist HPA South West Isabel.oliver@hpa.org.uk www.webbertraining.com The Health Protection Agency Mumps Control of mumps Epidemiology
More informationVERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance
Version No.: 1.0 Page 1 / 5 DOCUMENT ADMINISTRATION VERSION APPROVAL PROCESS DATE NUMBER 1.0 Nina Schwalbe, Managing Director, and Performance Reviewed by: GAVI Programme 23 April 2012 and Committee Approved
More informationDownloaded from:
Christensen, H; Trotter, CL; Hickman, M; Edmunds, WJ (2014) Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study. BMJ (Clinical research ed), 349.
More informationHighland NHS Board 6 October 2015 Item 5.1 NEW VACCINATION PROGRAMMES
Highland NHS Board 6 October 2015 Item 5.1 NEW VACCINATION PROGRAMMES Report by Abhayadevi Tissington, Nurse Consultant Health Protection and Ken Oates, Consultant in Public Health on behalf of Hugo Van
More informationTHE KEATS GROUP PRACTICE REGISTRATION FORM PLEASE COMPLETE IN BLOCK CAPITALS PERSONAL BACKGROUND INFORMATION
Registration checked by: Date: 11 & Under THE KEATS GROUP PRACTICE REGISTRATION FORM PLEASE COMPLETE IN BLOCK CAPITALS PERSONAL BACKGROUND INFORMATION Male Female Has your child ever been treated at this
More informationOVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE
OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE Dr Tiong Wei Wei, MD, MPH Senior Assistant Director Policy and Control Branch, Communicable Diseases Division Ministry of Health 9
More informationImmunisation Update for Occupational Health
Immunisation Update for Occupational Health Dr Gayatri Amirthalingam Immunisation, Hepatitis & Blood Safety department Public Health England 29 th April 2016 Session Outline Epidemiology of vaccine preventable
More informationIncreasing the uptake of MMR in London: executive summary of findings from the social marketing project, November 2009
Increasing the uptake of MMR in London: executive summary of findings from the social marketing project, November 2009 1 Introduction & approach The London Social Marketing Unit (LSMU joined in April 2009)
More informationProgress in maternal and child health: Uzbekistan and WHO European Region
Progress in maternal and child health: Uzbekistan and WHO European Region The National Model of Maternal and Child Health Protection in Uzbekistan: Zsuzsanna Jakab WHO Regional Director for Europe UZBEKISTAN
More informationNHS public health functions agreement Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme
NHS public health functions agreement 2018-19 Service specification No.6 Meningococcal C (MenC) containing vaccine immunisation programme 1 NHS public health functions agreement 2018-19 Service specification
More informationNHS GRAMPIAN IMMUNISATION PROGRAMMES ANNUAL REPORT 2010/11
NHS GRAMPIAN IMMUNISATION PROGRAMMES ANNUAL REPORT 2010/11 NHS GRAMPIAN IMMUNISATION STEERING GROUP March 2012 1 Table of Content 1. Purpose of this report.3 2. Uptake of immunisation: key points during
More informationSeasonality of influenza activity in Hong Kong and its association with meteorological variations
Seasonality of influenza activity in Hong Kong and its association with meteorological variations Prof. Paul Chan Department of Microbiology The Chinese University of Hong Kong Mr. HY Mok Senior Scientific
More informationBristol and South Gloucestershire School Aged Immunisation Pathways for the 2018/19 academic year
Bristol and South Gloucestershire School Aged Immunisation Pathways for the 2018/19 academic Introduction This information is aimed to support local practices in understanding school aged immunisations,
More informationThe National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.
The National Immunisation Schedule Update and Current issues Dr Brenda Corcoran National Immunisation Office Objectives To outline immunisation schedules in Ireland Primary childhood schedule Vaccine uptake
More informationReport to Health and Well- Being Board on Childhood Immunisation Programmes in Barnet 14 th September 2017/18
Report to Health and Well- Being Board on Childhood Immunisation Programmes in Barnet 14 th September 2017/18 Report on Section 7a Immunisation Programmes in London Borough of Barnet Prepared by: Amanda
More informationHistory and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8
History and aims of immunisation Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 Objectives To examine the history of immunisation To explain the aim of immunisation To develop
More informationHealthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
More information2017/18 Immunisation programmes list of additional and enhanced services
2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2017 Prepared
More informationHealthier Communities. Effective Governance
Our Key Priorities Effective Governance Healthier Communities Accessible and sustainable services Our values Excellent outcomes and experience Strong partnerships A Fully Engaged and Skilled Workforce
More informationDownloaded from:
Granerod, J; Davison, KL; Ramsay, ME; Crowcroft, NS (26) Investigating the aetiology of and evaluating the impact of the Men C vaccination programme on probable meningococcal disease in England and Wales.
More information2018/19 Immunisation programmes list of additional and enhanced services
2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2018 Prepared
More informationGUIDANCE ON PRESCRIBING VACCINATIONS ON THE NHS & PRIVATELY (INCLUDING TRAVEL VACCINATIONS)
GUIDANCE ON PRESCRIBING VACCINATIONS ON THE NHS & PRIVATELY (INCLUDING TRAVEL VACCINATIONS) Under the new GMS contract (from 2004), vaccinations and immunisations are paid for through various mechanisms
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 October 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 October 2009 MENINGITEC suspension for injection in prefilled syringes meningococcal group C oligosaccharide conjugate
More informationGlobal and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office.
Global and National Trends in Vaccine Preventable Diseases Dr Brenda Corcoran National Immunisation Office Global mortality 2008 Children under 5 years of age 1.5 million deaths due to vaccine preventable
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More informationThe power of partnership: the GAVI Alliance Board
The power of partnership: the GAVI Alliance Board 1 GAVI s mission To save children s lives and protect people s health by increasing access to immunisation in poor countries Strategic goals 2011 2015!
More information2016/17 Vaccination and Immunisation list of additional services and enhanced services
2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services Version number: 1 First published:
More informationInvasive Meningococcal Disease - prevention through vaccination
Invasive Meningococcal Disease - prevention through vaccination Dr Shamez Ladhani Paediatric Infectious Diseases Consultant Public Health England Email: shamez.ladhani@phe.gov.uk a pain you cannot describe
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No.7 Hib/MenC vaccination programme NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information
More informationNational Institute for Communicable Diseases -- Weekly Surveillance Report --
Weekly Surveillance Report Week 43, 216 National Institute for Communicable Diseases -- Weekly Surveillance Report -- Page 2 Laboratory-Based Respiratory & Meningeal Disease Surveillance 3 Neisseria meningitidis
More informationOpinion. Vaccination Programmes and Health Systems in the EU. Expert Panel on Effective Ways of Investing in Health
Opinion Vaccination Programmes and Health Systems in the EU Expert Panel on Effective Ways of Investing in Health Brussels, 13 September 2018 Expert Panel on Investing in Health Access to innovative medicines
More informationAnnual Immunisation and Vaccine Preventable Diseases Report for Northern Ireland
Annual Immunisation and Vaccine Preventable Diseases Report for Northern Ireland 2016-17 Acknowledgements The Public Health Agency immunisation team would like to thank everyone who works so hard across
More informationNHSE London Immunisation 2 year Plan
NHSE London Immunisation 2 year Plan 2017/18 2018/19 July 2017 Vision Empower and protect Londoners from vaccine preventable diseases Outcome One Improved patient experience and empowerment, measured through
More informationVACCINES FOR ADULTS. Developing an Underutilised Health Resource. 13 November 2007
VACCINES FOR ADULTS Developing an Underutilised Health Resource 13 November 2007 OUTLINE background to adult immunisation in Canada roles and recommendations of immunisation advisory committees in Canada
More informationCommunicable Disease Control and Vaccine Preventable Diseases/Update and Impact. Agenda
Communicable Disease Control and Vaccine Preventable Diseases/Update and Impact Communicable Disease Control and Prevention Bureau (CDCP) Communicable Disease Epidemiology Section (CDEpi) Agenda Communicable
More informationImmunisations at secondary school Your questions answered
Immunisations at secondary school Your questions answered about the HPV and Td/IPV vaccinations given between 12 and 18 years of age (school years 8 to 13) the safest way to protect your health Introduction
More informationWELSH HEALTH CIRCULAR
WELSH HEALTH CIRCULAR WHC (2015) 037 Issue Date: 23 July 2015 STATUS: ACTION CATEGORY: HEALTH PROFESSIONAL LETTER Title: Meningococcal ACWY conjugate vaccination (MenACWY) Date of Expiry / Review N/A For
More informationChanges to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25
Changes to the meningococcal C conjugate (MenC) vaccine schedule 2014 first-time university entrants under the age of 25 An update for registered healthcare practitioners August 2014 Quality Education
More informationChanges to the meningococcal C conjugate (MenC) vaccine schedule Information for healthcare professionals
Changes to the meningococcal C conjugate (MenC) vaccine schedule 2013-2015 Information for healthcare professionals 1 About Public Health England Public Health England s mission is to protect and improve
More informationAccess to vaccination in GAVI countries and at global level
Access to vaccination in GAVI countries and at global level Stefano Malvolti Director, Vaccine Implementation GAVI Alliance 15th ADVANCED COURSE OF VACCINOLOGY May 12, 2014 Global progress to MDG 4 for
More informationImmunisations at secondary school
Immunisations at secondary school Your questions answered about the HPV, Td/IPV and MenC vaccinations given between 12 and 14 years of age (school years 8 to 9/10) Includes two-dose HPV schedule from September
More informationDirector of Public Health Board Paper No. 13/13
Greater Glasgow and Clyde NHS Board Director of Public Health Board Paper No. 13/13 Report of the Director of Public Health : Major Development to Immunisation Programmes in Scotland Implications for NHSGGC
More information7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids
7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids Contents Introduction Nunavut Recommended Childhood Immunization Schedule Nunavut Routine Adult Immunization Schedule Nunavut Immunization
More informationCurrent National Immunisation Schedule Dr Brenda Corcoran National Immunisation Office.
Current National Immunisation Schedule 2012 Dr Brenda Corcoran National Immunisation Office Objectives To outline immunisation schedules in Ireland Primary childhood schedule Vaccine uptake rates School
More informationChallenges of building a new vaccine delivery platform for LMICs
Challenges of building a new vaccine delivery platform for LMICs Terri B. Hyde, MD MPH Immunizations Systems Branch, GID, CDC 23 March 2017 Immunization in the Elderly Geneva, Switzerland What has been
More informationNational Pandemic Vaccination Programme
March 2010 National Pandemic Vaccination Programme Swine Flu Vaccination Programme Pneumococcal Catch-up Campaign Measles Outbreak National Immunisation Guidelines NIO Website HPV Vaccine Campaign Vaccine
More informationAdult Immunizations. Business Health Care Group (BHCG) April 25, Cathy Edwards. Immunization Program Advisor
Adult Immunizations Business Health Care Group (BHCG) April 25, 2012 Cathy Edwards Immunization Program Advisor Wisconsin Department of Health Services Division of Public Health 1 Adult Immunizations WHY
More informationImmunization Report Public Health September 2013
Immunization Report Public Health September 2013 Daycare, school entry and school program immunization enrollment rates, up to 2012 Table of Contents 1. Introduction... 2 2. Data Source... 2 3. Limitations...
More informationHelp protect your baby against MenB
Help protect your baby against MenB 2015 New vaccine for babies available from 1 September 2015 1 From 1 September 2015, all babies born on or after 1 July 2015 will be offered the MenB vaccine along with
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationPublic Health Wales Vaccine Preventable Disease Programme
Public Health Wales Vaccine Preventable Disease Programme LHB practice level reports Cwm Taf LHB July June August Page of Contents. Purpose and Background.... LHB Summary.... Practice level data Merthyr
More informationWhy is surveillance important after introducing vaccines?
Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March
More informationIntroduction of new vaccines: public health - policy decisions and programmatic implications
Network for Education and Support in Immunisation Introduction of new vaccines: public health - policy decisions and programmatic implications André Meheus & Fred van der Veen SAVIC-Gauteng 2009 EPI symposium
More informationGavi s Vaccine Investment Strategy
Gavi s Vaccine Investment Strategy Judith Kallenberg, Head of Policy WHO Product Development for Vaccines Advisory Committee Meeting Geneva, Switzerland, 7-9 September 2015 www.gavi.org Vaccine Investment
More informationVaccine Decision-Making
Key Points Vaccine Decision-Making * Decisions on introducing new vaccines have long-term implications for immunization costs as well as logistics systems and service delivery. The choice of vaccine presentation
More informationGOVERNING BOARD. Date of Meeting 15 May 2013 Agenda Item No 13. Title Immunisation and Vaccination Report 2012/13
GOVERNING BOARD Date of Meeting 15 May 2013 Agenda Item No 13 Title Immunisation and Vaccination Report 2012/13 Purpose of Paper To update the CCG on the performance and quality of vaccination programmes
More informationCyprus Experience. Dr. Elena Papamichael Ministry of Health
Cyprus Experience Dr. Elena Papamichael Ministry of Health Cyprus became independent on1960. On 1974, Turkish troops invaded in the island disturbing the willing for peaceful living. Since then, Turkey
More informationNational Vaccine Plan: From Strategy to Implementation
National Vaccine Plan: From Strategy to Implementation July 26, 2011 Sarah Landry Senior Advisor, National Vaccine Program Office Office of the Assistant Secretary for Health Department of Health and Human
More informationLocal Enhanced Service Specification. MenACWY vaccination programme for 15 and 16 year olds (school year 11) in Cornwall and the Isles of Scilly
Local Enhanced Service Specification MenACWY vaccination programme for 15 and 16 year olds (school year 11) in Cornwall and the Isles of Scilly 1 st January 2016 to 31 st August 2016 1 Local Enhanced Service
More informationNCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits
NCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits Overall Goal: To identify strategies for providing comprehensive care during a well visit. The provision of comprehensive
More informationEthics Perspective of Immunisation Programs
Ethics Perspective of Immunisation Programs with special reference to Herd Effect T Jacob John Vellore, India Annecy 26 October 2010 Defining Herd immunity and Herd effect. Between participants and nonparticipants
More informationHAEMOPHILUS INFLUENZAE INVASIVE DISEASE
23 Annual Morbidity Report HAEMOPHILUS INFLUENZAE INVASIVE DISEASE CRUDE DATA 35 Annual Incidence a LA County.37 California b. United States c.2 Age at Diagnosis Mean 4. years Median 36. years Range Birth
More informationVII THE CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE 7. 7
VII THE CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE IMMUNISATION PROGRAMME IN 2002 7. 7 The childhood immunisation programme in Singapore offers vaccination against tuberculosis, hepatitis B, diphtheria,
More informationVaccine Introduction & Uptake Timing Benchmark Project
Vaccine Introduction & Uptake Timing Benchmark Project Lois Privor-Dumm Managing Director Policy, Advocacy & Communications Team Lead International Vaccine Access Center Johns Hopkins Bloomberg School
More informationRESEARCH. Economic evaluation of human papillomavirus vaccination in the United Kingdom
Economic evaluation of human papillomavirus vaccination in the United Kingdom Mark Jit, health economist and mathematical modeller, Yoon Hong Choi, mathematical modeller, WJohnEdmunds,headofmodellingandeconomicsunit
More informationImmunisation in Shetland
Immunisation in Shetland Annual Report 2011-12 The two public health interventions that have had the greatest impact on the world s health are clean water and vaccines World Health Organisation October
More informationImmunisation in Shetland
Immunisation in Shetland Annual Report 2010-11 The two public health interventions that have had the greatest impact on the world s health are clean water and vaccines World Health Organisation August
More informationGENERAL PRACTITIONER DATA PACK GUIDANCE
RESTRICTED For CQC internal use only This should NOT be shared outside CQC GENERAL PRACTITIONER DATA PACK GUIDANCE PRIMARY CARE DATA PACKS AND INSPECTION TEAM - November 2015 - Table of Contents Introduction...
More informationRisk and Uncertainty. The Precautionary Principle: Immunisation safety: risks, benefits and precautions.
Risk and Uncertainty The Precautionary Principle: Immunisation safety: risks, benefits and precautions. Prof. David Salisbury CB Director of Immunisation, Department of Health. The precautionary principle
More informationVaccinating special risk groups/responding to outbreaks. VACCSline
Vaccinating special risk groups/responding to outbreaks 2016 Protecting vulnerable persons Raise awareness of recommendations for certain patients Apply this to own workplace when developing immunisation
More informationThe Financial Sustainability of New Vaccine Introduction in the Poorest Countries :
The Financial Sustainability of New Vaccine Introduction in the Poorest Countries : Evidence from the First Phase of GAVI (Global Alliance for Vaccines and Immunization) Patrick Lydon lydonp@who.int Session:
More informationEvery Opportunity in Partnership.. Child & Family Service working in Partnership to increase Human Papilloma Virus (HPV) coverage rates
Every Opportunity in Partnership.. Child & Family Service working in Partnership to increase Human Papilloma Virus (HPV) coverage rates Lorraine Glover [Immunisation Nurse Consultant] HUMAN PAPILLOMA VIRUS
More informationHPV, Cancer and the Vaccination Programme
HPV, Cancer and the Vaccination Programme Dr Brenda Corcoran Consultant in Public Health Medicine HSE National Immunisation Office What is HPV? Human papillomavirus Over 200 types identified Spread by
More informationEpidemiology and Control of Pertussis in England: Impact of Maternal Immunisation Dr Gayatri Amirthalingam
Epidemiology and Control of Pertussis in England: Impact of Maternal Immunisation Dr Gayatri Amirthalingam Immunisation, Hepatitis & Blood Safety department Public Health England 12 th November 2015 Session
More informationThe HPV Immunisation Programme in NZ. Chris Millar Senior Advisor Immunisation Ministry of Health
The HPV Immunisation Programme in NZ Chris Millar Senior Advisor Immunisation Ministry of Health chris_millar@moh.govt.nz 4 September 2015 Background of NZ s HPV Immunisation Programme Aim: To protect
More informationLocal CQUIN Template School Aged Immunisation Programmes
Local CQUIN Template Aged Immunisation Programmes 2017-2019 Indicator number Indicator name Aged Immunisation Programmes 2017-2019: Ensuring a wide spread of good coverage Indicator weighting (% of CQUIN
More informationMarc Baguelin 1,2. 1 Public Health England 2 London School of Hygiene & Tropical Medicine
The cost-effectiveness of extending the seasonal influenza immunisation programme to school-aged children: the exemplar of the decision in the United Kingdom Marc Baguelin 1,2 1 Public Health England 2
More informationO N E R O O T, M A N Y R O U T E S Impact of User-Based System Design on Immunization Delivery
O N E R O O T, M A N Y R O U T E S Impact of User-Based System Design on Delivery CPHA 2016 Health Protection June 14, 2016 Authors Rosalie Tuchscherer, Saskatchewan Ministry of Health Jill Reedijk, British
More information